Skip to Content

Compugen Ltd CGEN

Morningstar Rating
$1.79 −0.08 (4.21%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CGEN is trading at a 448% premium.
Price
$1.87
Fair Value
$8.32
Uncertainty
Very High
1-Star Price
$8.86
5-Star Price
$9.34
Economic Moat
Fwl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.87
Day Range
$1.751.90
52-Week Range
$0.533.03
Bid/Ask
$1.79 / $1.80
Market Cap
$160.37 Mil
Volume/Avg
160,449 / 346,886

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.59
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
68

Comparables

Valuation

Metric
CGEN
GMDAQ
NUVL
Price/Earnings (Normalized)
Price/Book Value
2.817.63
Price/Sales
4.590.82
Price/Cash Flow
Price/Earnings
CGEN
GMDAQ
NUVL

Financial Strength

Metric
CGEN
GMDAQ
NUVL
Quick Ratio
4.290.2720.70
Current Ratio
4.290.3520.93
Interest Coverage
Quick Ratio
CGEN
GMDAQ
NUVL

Profitability

Metric
CGEN
GMDAQ
NUVL
Return on Assets (Normalized)
−17.97%−72.65%−21.42%
Return on Equity (Normalized)
−26.93%−22.49%
Return on Invested Capital (Normalized)
−30.22%−103.76%−26.50%
Return on Assets
CGEN
GMDAQ
NUVL
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
CcvvppgknlKvr$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
KymhsqlwySbwrlmj$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
KytnqwsrpHgczcd$117.6 Bil
Moderna Inc
MRNA
SqtqdrzSqy$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
XlcygvqcQlltggn$29.9 Bil
argenx SE ADR
ARGX
QklqnrdcJqwvk$27.7 Bil
BioNTech SE ADR
BNTX
CkvbmlbgQnjn$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
BcnzyvdzXvgjn$15.8 Bil
United Therapeutics Corp
UTHR
RrdlwjkrzPxdq$14.6 Bil
Incyte Corp
INCY
ZdtbyjvsmBfhjfb$12.9 Bil

Sponsor Center